Margaret Patrick
Margaret Patrick joined Market Realist in September 2014 and has written close to 3,000 articles. She has covered the healthcare sector, which includes pharmaceutical and biotechnology companies, medical device companies, health insurance companies, and hospital companies. Currently, she is following the cannabis sector.
Prior to joining Market Realist, Margaret worked as equity and data analyst at MSCI for a year and as a financial research analyst at Deloitte for two years. She completed her MBA with finance specialization in 2011. She also passed all three CFA levels.
Besides writing on stocks, Margaret loves to read about nutrition, culture, and mythology. She's also fond of traveling to new places.
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Margaret Patrick
AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
AbbVie (ABBV) has completed enrollment in its Phase 3 pivotal trials testing investigational therapy risankizumab as a treatment option for psoriasis.
Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain
AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.
AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug
Imbruvica expected to aggressively penetrate in first-line CLL segment based on data from multiple ongoing clinical studies.
Teva’s Research Pipeline to Culminate in Many New Drug Launches?
Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.
Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market
In 3Q16, Biogen’s (BIIB) oral multiple sclerosis (or MS) drug, Tecfidera, managed to increase its global market share to ~15%, a year-over-year (or YoY) rise of about 1 point.
Xalkori Label Expansion May Boost Pfizer’s Sales in 2016
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
Viagra May Witness a Decline in Revenues in 2016
Wall Street analysts estimate that Viagra’s sales in 2016 will reach approximately $1.6 billion, which would be a year-over-year (or YoY) decline of about 7.7%.
Pfizer Has a Revenue-Boosting Treatment to Help Smokers Quit
Approved by the FDA on May 11, 2006, Chantix, also known as Champix, is used as an aid to help cigarette smokers quit the habit of smoking.
Will Novo Nordisk’s Core Capabilities Be Enough to Differentiate Its Research Pipeline?
Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline.
Novo Nordisk Expects to Witness Strong Growth from New Product Launches
In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.
Can Novo Nordisk Continue to Maintain Market Share in Modern Insulin?
Despite strong competition from new generation insulin therapies, Novo Nordisk (NVO) has managed to maintain its market share in the modern insulin market.
Novo Nordisk Is Expected to See Strong Growth in Insulin Segment
Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.
Teva Has a Targeted Strategy to Expand in Major Growth Markets
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
Teva Pharmaceutical Still Dominates the Generic Market in Europe
With a share of about 14%, Teva Pharmaceutical Industries (TEVA) is currently the top-ranking player in the European generic pharmaceutical market.
A Look at Teva’s Dominance in the Biosimilar Space
As one of the early entrants in biosimilars, Teva Pharmaceutical Industries (TEVA) has managed to become one of the biggest players in the biosimilar space.
Teva Is Well Positioned for New Trends in the US Generic Market
Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market.
Teva’s OTC Business Is Playing out to Be a Key Growth Driver
In addition to its generic pharmaceutical business, Teva Pharmaceutical also has a significant presence in the major categories of the OTC drug business.
Teva’s Generic Value Chain Differentiates It from Its Peers
In addition to its robust strategy, Teva Pharmaceutical also boasts of an extensive presence across all levels of the value chain for its generics business.
Winning? We Review How Teva Dominates Generic Drug Space
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
United Therapeutics’ Research Efforts Key to Boosting Stock
While multiple drugs are available for Group 1 PAH patients, there are currently no approved drugs in the market for Group 2, 3, or 5 PAH patients.
AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494
Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.
How AbbVie Expects Risankizumab to Be a Transformative Therapy
AbbVie (ABBV) expects its investigational drug Risankizumab to be a transformative therapy for psoriasis.
Teva Pharmaceutical: A Successful Bond Financing Program in 2016
To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.
Teva’s Asthma Segment: What Could Boost Its Revenues in 2016?
On March 23, 2016, the FDA approved Cinqair (reslizumab) as a maintenance therapy for patients with severe asthma.
Amgen’s Bone Health Drug Saw Strong Revenue Growth in 2Q16
Amgen’s (AMGN) bone health drugs Prolia and Xgeva earn a combined $3 billion in revenue annually.
ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.
Why Is AbbVie’s Valuation Multiple Rising in July?
AbbVie believes that the Market has misunderstood the growth potential of Rova-T, which is expected to earn $1.5 billion–$2 billion in peak sales even under extremely conservative assumptions.
Why AbbVie Expects Rova-T to See Big Peak Sales
AbbVie project that Rova-T, a DLL3-targeted antibody conjugate acquired through the acquisition of Stemcentrx, will earn $5 billion in peak sales.
Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
AbbVie hopes to position Imbruvica as a therapy for multiple indications: follicular lymphoma, solid tumor, and diffuse large B-cell lymphoma, among others.
Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors.
Understanding Trinity: Inside the Testing of AbbVie’s Rova-T
Trinity is a phase-2 clinical trial that tests the use of Rova-T as a third-line therapy for SCLC (small cell lung cancer).
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
Can Stemcentrx’s Cancer Stem Cell Technology Really Accelerate Innovation for AbbVie?
The acquisition of Stemcentrx has added CSC (cancer stem cell) technology platform to AbbVie’s (ABBV) oncology portfolio.
Venclexta: The First BCL-2 Inhibitor Cancer Therapy to Be Approved by the FDA
On April 11, 2016, Venclexta became the first BCL-2 inhibitor therapy to be approved by the FDA for chronic lymphocytic leukemia patients with 17p deletion.
Inside Gilead Sciences’ Involvement in TAF Therapies
On March 01, 2016, the FDA approved Gilead Sciences’ TAF-based HIV drug, Odefsey, for the treatment of certain HIV-1 afflicted patients.
Otezla Captures Psoriasis and Psoriatic Arthritis Market Shares
Celgene (CELG) expects Otezla to earn revenue of up to $1 billion in 2016 and in the range of $1.5 billion–$2 billion in 2017.
Celgene Continues to Develop New Multiple Myeloma Drugs
Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.
Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016
If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.
Inside Quest Diagnostics’ Growth Restoration Strategy
Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.
Understanding Quest Diagnostics’ Valuation Multiple Compared to Those of Peers
Quest Diagnostics trades at a premium multiple compared to Lab Corp of America and at a big discount compared to peers Davita Healthcare and IDEXX Labs.
Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?
If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.
Bendeka: How Teva Plans to Safeguard Oncology Revenues
In the first quarter of 2016, Teva Pharmaceutical Industries (TEVA) launched a new drug, Bendeka, in partnership with Eagle Pharmaceuticals.
How Could Generic Competition Affect Copaxone’s Revenues in 2016?
Wall Street analysts have projected that Teva Pharmaceutical Industries (TEVA) will earn about $3.5 billion in revenues from Copaxone sales in 2016
Why Did Amgen Implement Multi-Pronged Strategy for Repatha?
Amgen (AMGN) is expecting to strengthen Repatha’s brand position in the global cardiovascular market in 2016 through a multi-pronged strategy.
Amgen’s Neupogen and Neulasta: Why Are They Losing Market Share?
Amgen expects Neupogen to lose market share in 2016. In 2015, Neupogen lost 3% market share in the United States due to biosimilar competition and branded competition.
Romosozumab: Will It Benefit Amgen in the Future?
In 1Q16, Amgen expects to have data from its Phase 3 clinical trial exploring the use of innovative drug romosozumab for treating post-menopausal osteoporosis.
What Could Drive Amgen’s Kyprolis Sales in 2016?
Amgen expects Kyprolis to continue capturing the global multiple myeloma (or MM) market in 2016. The drug has established itself as a backbone therapy for relapsed MM.
AbbVie’s Therapies in Virology, Neurology, and Women’s Health
In addition to its Oncology and Immunology segments, AbbVie is focused on launching innovative therapies in its Virology, Neurology, and Women’s Health segments.
HCA Holdings’s Strong Capital Expenditure Strategy for 2016
In 2015, HCA Holdings deployed ~$2.4 billion in capital expenditure. It planned to increase capital spending to $2.7 billion in 2016.
AbbVie’s Net Profit Margin Expected to Reach 29.8% in 4Q15
AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%.